% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{TurzanskiFortner:276228,
      author       = {R. Turzanski-Fortner$^*$ and C. B. Trewin-Nybråten and T.
                      Paulsen and H. Langseth},
      title        = {{C}haracterization of ovarian cancer survival by histotype
                      and stage: {A} nationwide study in {N}orway.},
      journal      = {International journal of cancer},
      volume       = {153},
      number       = {5},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2023-01037},
      pages        = {969-978},
      year         = {2023},
      note         = {#EA:C020# / 2023 Sep 1;153(5):969-978},
      abstract     = {Contemporary population-based data on ovarian cancer
                      survival using current subtype classifications and by
                      surgical status are sparse. We evaluated 1-, 3-, 5- and
                      7-year relative (and overall) survival, and excess hazards
                      in patients with borderline tumors or invasive epithelial
                      ovarian cancer diagnosed 2012 to 2021 in a nationwide
                      registry-based cohort in Norway. Outcomes were evaluated by
                      histotype, FIGO stage, cytoreduction surgery and residual
                      disease. Overall survival was evaluated for non-epithelial
                      ovarian cancer. Survival of women with borderline ovarian
                      tumors was excellent $(≥98.0\%$ 7-year relative survival).
                      Across all evaluated invasive epithelial ovarian cancer
                      histotypes, 7-year relative survival for cases diagnosed
                      with stages I or II disease was $≥78.3\%$ (stage II
                      high-grade serous). Survival for ovarian cancers diagnosed
                      at stage ≥III differed substantially by histotype and time
                      since diagnosis (eg, stage III, 5-year relative survival
                      from $27.7\%$ [carcinosarcomas] to $76.2\%$ [endometrioid]).
                      Overall survival for non-epithelial cases was good $(91.8\%$
                      5-year overall survival). Women diagnosed with stage III or
                      IV invasive epithelial ovarian cancer and with residual
                      disease following cytoreduction surgery had substantially
                      better survival than women not operated. These findings were
                      robust to restriction to women with high reported functional
                      status scores. Patterns for overall survival were similar to
                      those for relative survival. We observed relatively good
                      survival with early stage at diagnosis even for the high
                      grade serous histotype. Survival for patients diagnosed at
                      stage ≥III invasive epithelial ovarian cancer was poor for
                      all but endometrioid disease. There remains an urgent need
                      for strategies for risk reduction and earlier detection,
                      together with effective targeted treatments.},
      keywords     = {cytoreduction surgery (Other) / histotype (Other) / ovarian
                      cancer (Other) / stage (Other) / survival (Other)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37226635},
      doi          = {10.1002/ijc.34576},
      url          = {https://inrepo02.dkfz.de/record/276228},
}